Pay in 4 interest-free payments of $5.39 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
Sources: Novo press release, cms.gov, Institute for Clinical and Economic Review, ro.com
Our results are clinically relevant and consistent with clinical reports that the secretory capacity of -cell was diminished in first-degree relatives of individuals with T2DM even before the onset of obesity and insulin resistance 32
Obstructive Sleep Apnea SURMOUNT-OSA trials investigated GLP2 in adults with moderate-to-severe obstructive sleep apnea and obesity: Significant improvements in apnea-hypopnea index (AHI) from baseline Benefits observed in participants both using and not using positive airway pressure therapy Improvements correlated with weight reduction FDA approval granted in December 2024 for moderate-to-severe OSA treatment Diabetes Prevention Extended follow-up from SURMOUNT-1 assessed diabetes prevention in participants with prediabetes: 94% reduction in progression to type 2 diabetes compared to placebo over 3 years Nearly all participants with prediabetes at baseline converted to normoglycemia Effects diminished during off-treatment follow-up period, indicating ongoing treatment benefit [CALLOUT BOX Highlighted] Important Context: While GLP2 has demonstrated substantial efficacy in multiple large-scale clinical trials, the majority of data comes from industry-sponsored studies with relatively short follow-up periods (40-72 weeks for most trials)
The Bottom Line BPC-157, GHK-Cu, and TB-500 are often grouped together because they are all discussed in the context of healing and regeneration
Nonfatal stroke risk was decreased by 16% and hospitalization for heart failure by 10%
There is growing evidence that GLP-1 and GLP-1 RA might play a strategic role in mammalian reproduction as a new metabolic signal in the reproductive system
